Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Child and Adolescent Psychiatry and Mental Health

Figure 1

From: Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

Figure 1

Figure 1 shows the effect sizes of atomoxetine in improving CHIP-CE scores, by age groups, based on data of the 3 placebo-controlled trials. P values are based on treatment differences within age groups and are shown by astericks, as follows: *p≤0.05; **p≤0.01; ***p≤0.001.

Back to article page